五分割消融性磁共振引导自适应放疗联合选择性淋巴结照射治疗不可手术胰腺癌
该单中心回顾性研究纳入35例不可手术胰腺癌患者,采用磁共振直线加速器在吸气中期屏气下实施五分割消融性立体定向磁共振引导自适应放疗(SMART),中位总剂量50 Gy(BED10 100 Gy10),57.1%接受选择性淋巴结照射。中位随访10.3个月,3级急性和晚期毒性均仅2.9%,1年局部控制率87.8%、总生存率58.9%,提示该技术毒性低且早期局部控制令人鼓舞。
要点
- 五分割消融性SMART在不可手术胰腺癌中3级毒性发生率低(急性和晚期均2.9%)。
- 1年局部控制率87.8%、总生存率58.9%,早期疗效令人鼓舞。
- 该技术无需植入 fiducial 标记,采用连续分次内MR可视化和自动束流触发。
核心结论
- 五分割胰腺SMART在MR直线加速器上实施,观察到严重治疗相关毒性极少且早期局部控制令人鼓舞。
- 有必要前瞻性验证剂量强化SMART的可行性和长期临床结局。
研究设计与样本
- 单中心回顾性分析连续35例接受SMART的胰腺癌患者,采用MR直线加速器在吸气中期屏气下治疗。
- 80%为局部晚期疾病,91.4%在立体定向体部放疗前接受中位3.9个月的诱导化疗。
- 所有患者处方5次连续日照射,中位总剂量50 Gy(BED10 100 Gy10),通常热点为120%至130%。
- 20例(57.1%)接受选择性淋巴结照射;无患者放置 fiducial 标记,均采用连续分次内MR可视化和自动束流触发。
主要发现
- 自SMART起中位随访10.3个月,急性3级毒性发生率为2.9%,晚期3级毒性发生率为2.9%。
- 1年局部控制率为87.8%,远处转移无生存率为63.1%,无进展生存率为52.4%,病因特异性生存率为77.6%,总生存率为58.9%。
关键数值与推荐
- 处方剂量为5次连续日照射,中位总剂量50 Gy(BED10 100 Gy10),通常热点为120%至130%。
- 20例(57.1%)患者接受选择性淋巴结照射。
临床怎么用
- 对于不可手术胰腺癌,可考虑采用五分割消融性SMART联合选择性淋巴结照射,利用分次内MR可视化实现安全剂量递增。
- 治疗中无需放置 fiducial 标记,采用连续分次内MR可视化和自动束流触发进行靶区追踪。
局限性
- 本研究为单中心回顾性分析,样本量35例,随访时间较短(中位10.3个月)。
- 需要前瞻性研究确认可行性和长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy dose escalation using stereotactic body radiation therapy may significantly improve both local control (LC) and overall survival (OS) for patients with inoperable pancreas cancer. However, ablative dose cannot be routinely offered because of the risk of causing severe injury to adjacent normal organs. Stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) represents a novel technique that may achieve safe delivery of ablative dose and improve long-term outcomes. METHODS AND MATERIALS: We performed a single institution retrospective analysis of 35 consecutive pancreatic cancer patients treated with SMART in mid-inspiration breath hold on an MR-linear accelerator. Most had locally advanced disease (80%) and received induction chemotherapy (91.4%) for a median 3.9 months before stereotactic body radiation therapy. All were prescribed 5 fractions delivered in consecutive days to a median total dose of 50 Gy (BED10 100 Gy10), typically with a 120% to 130% hotspot. Elective nodal irradiation was delivered to 20 (57.1%) patients. No patient had fiducial markers placed and all were treated with continuous intrafraction MR visualization and automatic beam triggering. RESULTS: With median follow-up of 10.3 months from SMART, acute (2.9%) and late (2.9%) grade 3 toxicities were uncommon. One-year LC, distant metastasis-free survival, progression-free survival, cause-specific survival, and OS were 87.8%, 63.1%, 52.4%, 77.6%, and 58.9%, respectively. CONCLUSIONS: To our knowledge, this is the first report of 5-fraction pancreas SMART delivered on an MR-linear accelerator. We observed minimal severe treatment-related toxicity and encouraging early LC. Prospective confirmation of feasibility and long-term clinical outcomes of dose intensified SMART is warranted.
引用
- Chuong MD, Bryant J, Mittauer KE, et al. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer. Pract Radiat Oncol. 2020. PMID: 32947042. doi:10.1016/j.prro.2020.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。